Trabectedin Cardiotoxicity in Soft Tissue Sarcoma: A Case Series and Clinical Insights

• DOI: 10.1159/000526256
• Publication Date: 2022-11-08T22:00:59Z
• Authors: David G. Gent; Nasim Ali; Anna Olsson-Brown; Gregory Y.H. Lip; David J. Wright; Rebecca Dobson
• Keywords: Cardiotoxicity; Trabectedin

Trabectedin is a chemotherapeutic used to treat advanced soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer. Although it associated with low incidence of cardiotoxicity, when this occurs can be fatal or significantly compromise the quality life in patients Here, we present series 4 cases where trabectedin-treated developed cardiovascular complications. Similar previous literature describing association, all had prior treatment anthracyclines presented at different time points following initiation. Each patient exertional breathlessness was found have severely impaired left ventricular systolic function (ejection fraction ≤35%), 1 concurrent atrial fibrillation fast rate. All were treated neurohormonal blockade, multi-disciplinary decision made stop trabectedin 3 continue patient. Two an improvement their function. It unclear what effect preceeding anthracycline tyrosine kinase inhibitor has priming develop cardiotoxicity setting. Our case adds evidence surrounding association highlights that trabectedin-associated insidious fashion.